生物技术公司Invivyd, Inc.宣布,其Revolution项目取得重要进展,正加速推进新型麻疹单克隆抗体候选药物Vms063的研发。该药物具备成为同类首创及最优疗法的潜力,旨在用于麻疹的治疗与预防。
生物技术公司Invivyd, Inc.宣布,其Revolution项目取得重要进展,正加速推进新型麻疹单克隆抗体候选药物Vms063的研发。该药物具备成为同类首创及最优疗法的潜力,旨在用于麻疹的治疗与预防。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.